Axogen Inc (FRA:LT3)
€ 7.15 -0.15 (-2.05%) Market Cap: 310.95 Mil Enterprise Value: 358.92 Mil PE Ratio: 0 PB Ratio: 3.58 GF Score: 75/100

AxoGen Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 05:45PM GMT
Release Date Price: €9.05 (-6.22%)
Unidentified Analyst

Thank you all for joining us today. My name is Caroline Borowski and I'm a team member here at the JPMorgan Healthcare Group. It is my pleasure to introduce Karen Zaderej, the Chairman, CEO and President of AxoGen. And here, we also have Peter Mariani, the Executive Vice President and CFO; as well as Ed Joyce, Director of IR.

Karen Zaderej
AxoGen, Inc. - Chairman, President & CEO

Thank you, and thank you for inviting me to speak today. I'm here to tell you a little bit about AxoGen. So AxoGen is a company that's entirely focused in the area of peripheral nerve repair. And we find peripheral nerves are impacted in many ways across many stages of life, and we want to be able to provide solutions to patients to have a better quality of life by fixing those issues.

So a lot of people don't really think about peripheral nerves or know what they do. So we'd like to do the analogy that nerves are like the wires of your body. They carry signals to allow you to have muscle function, to know to move your muscles or to give you feedback from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot